On April 30, the National Health Insurance Administration released the "Evaluation Results of "Particularly Serious" and "Serious" Untrustworthiness in Price Procurement Credit Evaluation (Phase 9).
Entrusted by the National Health Security Administration, the National Health Security Administration's Pharmaceutical Price and Bidding and Procurement Guidance Center has summarized the situation of pharmaceutical enterprises rated as "particularly serious" and "serious" as of March 31, 2024 in various provinces, and the announcement is as follows.
"Particularly serious" dishonest →
Note 1: The credit rating of price solicitation is mainly determined based on the severity of the amount of bribes, unfair price behavior, and disruption of the order of centralized procurement. For example, a single bribe of more than 10,000 yuan is considered "average", a single bribe of more than 100,000 yuan is considered "moderate", a single bribe of more than 300,000 yuan is considered "serious", and a single bribe of more than 2 million yuan is "particularly serious".
Note 2: According to the credit rating of the pharmaceutical enterprise, measures such as reminding and admonishing, reminding the risk, and disclosing information on untrustworthiness may be taken, up to restricting or suspending the enterprise's involvement in the case or all drugs and medical consumables on the network, bidding or distribution qualifications. For example, for "serious" rated enterprises, measures such as canceling the qualifications of the products involved in the case are taken to be disposed of, and for "particularly serious" rated enterprises, measures such as canceling the qualifications of all their products are to be put on the network and distributed.
"Particularly serious" dishonest →
Recommended readings in previous issues
Blowing the evening breeze, blowing the bowl, and singing about youth, the romance of Lanzhou has just begun 🥳🥳🥳
